Enhertu shows positive results in DESTINY-Breast06 Phase III trial
Demonstrates statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
endocrine therapy
FDA approves Verzenio as the first and only CDK4/6 inhibitor for certain people with HR+HER2-…
Verzenio phase-III monarchE trial is a randomised (1:1), open-label, two cohort, multi-centre study in adult women and men with…